Hims & Hers Stock Drops Despite Higher Revenue Forecast: What Investors Need to Know
Hims & Hers Health shares fell sharply after the company reported a surprise first-quarter loss. Revenue also came in below what analysts expected. This news surprised many investors who had been optimistic about the company’s growth. The stock drop happened even though the company raised its full-year revenue forecast. This article explains what happened and what it means for investors.
What Did Hims & Hers Report?
For the first quarter of 2025, Hims & Hers reported a net loss. This was unexpected because analysts had predicted a small profit. The company lost money partly because it spent heavily on marketing and research. Revenue for the quarter was about $315 million. That was below the $325 million that Wall Street had expected. The company’s stock fell more than 15% in after-hours trading following the announcement.
Despite the weak first-quarter results, the company raised its full-year revenue forecast. Hims & Hers now expects revenue between $1.45 billion and $1.50 billion for 2025. That is up from its previous forecast of $1.40 billion to $1.45 billion. The company also projected strong second-quarter revenue of around $340 million. This shows that management believes the business will pick up later in the year.
Why Did the Stock Drop?
Investors focused on the bad news first. The surprise loss and the revenue miss were the main reasons for the stock drop. When a company misses earnings expectations, investors often sell shares. They worry that the business is not performing as well as hoped. In this case, the loss was a big disappointment. Hims & Hers had been profitable in previous quarters, so the loss was a surprise.
Another reason for the drop is regulatory uncertainty. Hims & Hers sells weight-loss drugs online. These drugs are in high demand. But the U.S. Food and Drug Administration (FDA) is looking at how these drugs are marketed and prescribed. There is concern that new rules could hurt the company’s sales. Investors are worried about what the FDA might do next.
What Is the Weight-Loss Drug Opportunity?
Hims & Hers has become a major player in the weight-loss drug market. The company offers compounded versions of popular drugs like semaglutide. These are cheaper than brand-name drugs. Many patients use them because they cannot afford the original medications. The weight-loss drug market is growing fast. Analysts expect it to be worth over $100 billion by 2030. Hims & Hers is trying to capture a big share of that market.
However, the FDA has raised concerns about compounded drugs. These drugs are not FDA-approved. They are made by special pharmacies. The FDA worries about safety and quality. In some cases, the FDA has warned patients to avoid compounded versions. This creates risk for Hims & Hers. If the FDA takes action, the company could lose a key source of revenue.
What Should Investors Watch For?
Investors should watch several things in the coming months. First, they should look at the company’s second-quarter results. If revenue comes in strong, it could calm fears. Second, they should follow FDA news. Any new rules on compounded drugs could affect the stock. Third, they should watch the company’s spending. If Hims & Hers can control costs, it could return to profitability.
Another thing to watch is competition. Many other companies are entering the weight-loss drug market. Hims & Hers faces rivals like Ro, Noom, and even big drugmakers. If competition increases, the company may have to lower prices. That could hurt profit margins.
Is Hims & Hers a Buy or Sell?
Opinions are mixed. Some analysts say the stock is a buy because of the strong revenue forecast. They believe the first-quarter loss was a one-time event. Others say the stock is risky because of regulatory uncertainty. They recommend waiting for more clarity. For general investors, it is important to do your own research. Consider your risk tolerance. Hims & Hers is a high-growth stock with high risk. It could go up a lot if things go well. But it could also fall sharply if problems arise.
In summary, Hims & Hers stock dropped because of a surprise loss and a revenue miss. The company raised its full-year forecast, which is a positive sign. But regulatory risks around weight-loss drugs remain a big concern. Investors should watch the next few quarters closely. The company’s future depends on how it handles these challenges.
